Rivas-Corchado LM, González-Geroniz M, Hernández-Herrera RJ

Language: Spanish
References: 16
Page: 562-568
PDF size: 252.33 Kb.

ABSTRACT

Background: In Mexico, ovarian cancer represents 5.3% of cancer diagnoses in all age groups and 21% of gynecologic cancers. The states with the highest incidence of this disease Nuevo León, Mexico State and Federal District.
Objective: To determine the epidemiological profile of ovarian cancer.
Patients and methods: A retrospective cross-sectional study that included all patients with complete records, diagnosed with ovarian cancer treated at the Oncology department UMAE Monterrey No. 23, January 2009 to 31 December 2009.
Results: We identified 40 patients with ovarian cancer. The average age of menarche was 12.7 years, 40% were of reproductive age, 25% were nulliparous, 15% had a pregnancy and 37.5% had two pregnancies. Of the total patients, 17% had a history of breast cancer, 40% used a contraceptive method, 37% used oral contraceptives. The tumor marker CA 125 was found in 40% of patients, 63.1% had ultrasound markers for cancer. The most frequent clinical stage 1A in which they found 32% of cases. Papillary serous adenocarcinoma was diagnosed in 25% of patients, endometroid adenocarcinoma and mucinous tumor of low malignant potential was diagnosed borderline at 20%, poorly differentiated adenocarcinoma in 18% tumor granulosa cells in 7% and papillary adenocarcinoma ring cell adenocarcinoma in 5%. In total, 43% of patients received chemotherapy.
Conclusion: The majority of cases tenía50 years or more. The background was the most frequent hereditary breast cancer. There were no deaths during the study.

REFERENCES

1. Mohar A, Frías-Mendivil MF, Suchil-Bernal L, Mora-Macías T, de la Garza J. Epidemiología descriptiva de cáncer en el Instituto Nacional de Cancerología de México. Salud Publica Mex 1997;39:1-6.

2. Instituto Nacional de Estadística, Geografía e Informática. II conteo de población y vivienda 2005. Base de datos 2005. www.inegi.org.mx/default.aspx

3. Cuevas-Urióstegui ML, Villasis-Keever MA, Fajardo-Gutiérrez A. Epidemiología del cáncer en adolescentes. Salud Publica Mex 2003;45(suppl 1):S115-S123.

4. Aronowitz RA. Unnatural history: breast cancer and American society. http://americancancersociety.org/downloads/STT/CAFF.finalPWsecured.pdf.

5. Sloots K, Ausems MGEM, de Haan HH. Ovarian cancer in BRCA-positive women: vigilance is mandatory despite screening programs. Euro- pean Journal of Obstetrics & Gynecology and Reproductive Biology 2002;101:196-198

6. Causas, factores de riesgo y prevención. http://www.cancer.org/Espanol/cancer/ovario/Guiadetallada/index.

7. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71:S517-S523.

8. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, et al. Carcinoma of the ovary. FIGO 6th annual Report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95,S161-S192.

9. Boyd J. BRCA: the breast, ovarian, and other cancer genes. Gynecol Oncol 2001;80:337-340.

10. Hightower RD, Nguyen HN, Averette HE, Hoskins W, et al. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 1994;73:377-383.

11. Ness RB, Cramer DW, Goodman MT, Kjaer SK, et al. Infertility, fertility drugs, and ovarian cancer: a poled analysis casecontrol studies. Am J Epidemiol 2002;155:217-224.

12. Rebbeck TR. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2000;18:100S-103S.

13. Valentin L, Ameye L, Testa A, Lécuru F, Bernard JP, et al. Ultrasound characteristics of different types of adnexal malignancies. Gynecol Oncol 2006;102:41-48.

14. DiSaia P. Oncología Ginecológica Clínica. 6ª ed. Harcourt, Elsevier Science, 2006.

15. Shingleton H, Fowler W, Jordan J, Lawrence W. Oncología ginecológica. México: McGraw-Hill Interamericana, 1998.

16. Te Linde. Ginecología quirúrgica. 9ª ed. Madrid, Médica Panamericana, 2006.